Wakana Yamashita, Yuta Sato, Matthew Imanaka, Michiyo Kataoka, Tadaki Suzuki, Aa Haeruman Azam, Shinjiro Ojima, Kayoko Hayakawa, Sho Saito, Yuki Moriyama, Norio Ohmagari, Masami Kurokawa, Kazuhisa Mezaki, Azumi Tamura, Longzhu Cui, Jumpei Fujiki, Hidetomo Iwano, Yoshimasa Takahashi, Koichi Watashi, Satoshi Tsuneda, Kotaro Kiga
Scientific Reports 2025年8月13日
<jats:title>Abstract</jats:title>
<jats:p>
<jats:italic>Stenotrophomonas maltophilia</jats:italic> is a bacterium often resistant to antibiotics and is a significant cause of nosocomial infections, particularly in immunocompromised patients. Phage therapy has shown promise as a potential treatment for such difficult-to-treat bacterial infections, but research on phages targeting this bacterium is very limited. In this study, we isolated 34 phages using four clinical strains of <jats:italic>S. maltophilia</jats:italic> and evaluated their infectivity and bactericidal activity. While some phages infected all four strains, many exhibited strain-specific infectivity. We investigated the bacterial growth curves in response to three phages, named Yut1, Yut2, and Yut4, and found that all phages exhibited potent lytic activity against the clinical strains even at low doses. Genome analysis found that the phages did not carry any lysogeny genes, virulence factors, or antibiotic resistance genes, suggesting their high potential as therapeutic phages. Furthermore, phylogenetic analysis suggested that Yut1 and Yut4 belong to a novel phage lineage. These results highlight the therapeutic potential of our novel phages to combat the growing antibiotic resistance problem.</jats:p>
https://orcid.org/0000-0002-8909-3885